Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DermGEN in diabetic foot ulcers
NCT02184455Phase 1Completed
- Start
- Jul 2016
- Primary completion
- May 2017
- Modality
- Tissue Cells, Hydrogel Systems
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of DermGEN in diabetic foot ulcer (DFU). Primary endpoint: Percentage of Wound Area Reduction Compared to Baseline at 4 weeks. Started Jul 2016; status: completed.
02
Drugs
DermGEN
03
Conditions
diabetic foot ulcer (DFU)
Beyond the preview
Go deeper on NCT02184455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02184455.